Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, McGinnis L, Hendricks R, Nutsch K, Banta KL, Duong E, Dunkle A, Chang PS, Han CJ, Mittman S, Molden N, Daggumati P, Connolly W, Johnson M, Abreu DR, Cho BC, Italiano A, Gil-Bazo I, Felip E, Mellman I, Mariathasan S, Shames DS, Meng R, Chiang EY, Johnston RJ, Patil NS. Guan X, et al. Among authors: felip e. Nature. 2024 Mar;627(8004):646-655. doi: 10.1038/s41586-024-07121-9. Epub 2024 Feb 28. Nature. 2024. PMID: 38418879 Free PMC article.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, McGinnis L, Hendricks R, Nutsch K, Banta KL, Duong E, Dunkle A, Chang PS, Han CJ, Mittman S, Molden N, Daggumati P, Connolly W, Johnson M, Abreu DR, Cho BC, Italiano A, Gil-Bazo I, Felip E, Mellman I, Mariathasan S, Shames DS, Meng R, Chiang EY, Johnston RJ, Patil NS. Guan X, et al. Among authors: felip e. Nature. 2024 Mar;627(8005):E11. doi: 10.1038/s41586-024-07280-9. Nature. 2024. PMID: 38480897 No abstract available.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, McGinnis L, Hendricks R, Nutsch K, Banta KL, Duong E, Dunkle A, Chang PS, Han CJ, Mittman S, Molden N, Daggumati P, Connolly W, Johnson M, Abreu DR, Cho BC, Italiano A, Gil-Bazo I, Felip E, Mellman I, Mariathasan S, Shames DS, Meng R, Chiang EY, Johnston RJ, Patil NS. Guan X, et al. Among authors: felip e. Nature. 2024 May 30. doi: 10.1038/s41586-024-07562-2. Online ahead of print. Nature. 2024. PMID: 38816613 No abstract available.
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L; DeLLphi-301 Investigators. Ahn MJ, et al. Among authors: felip e. N Engl J Med. 2023 Nov 30;389(22):2063-2075. doi: 10.1056/NEJMoa2307980. Epub 2023 Oct 20. N Engl J Med. 2023. PMID: 37861218 Clinical Trial.
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, Girard N, Patel VM, Takahama T, Owen SP, Reznick DM, Badin FB, Cicin I, Mekan S, Patel R, Zhang E, Karumanchi D, Garassino MC. Paz-Ares LG, et al. Among authors: felip e. J Clin Oncol. 2024 May 31:JCO2400733. doi: 10.1200/JCO.24.00733. Online ahead of print. J Clin Oncol. 2024. PMID: 38843511
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, Shaw AT, de Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Solomon BJ, et al. Among authors: felip e. J Clin Oncol. 2024 May 31:JCO2400581. doi: 10.1200/JCO.24.00581. Online ahead of print. J Clin Oncol. 2024. PMID: 38819031
The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project.
Sebri V, Marzorati C, Dorangricchia P, Monzani D, Grasso R, Prelaj A, Provenzano L, Mazzeo L, Dumitrascu AD, Sonnek J, Szewczyk M, Watermann I, Trovò F, Dollis N, Sarris E, Garassino MC, Bestvina CM, Pedrocchi A, Ambrosini E, Kosta S, Felip E, Soleda M, Roca AA, Rodríguez-Morató J, Nuara A, Lourie Y, Fernandez-Pinto M, Aguaron A, Pravettoni G. Sebri V, et al. Among authors: felip e. Cancer Med. 2024 May;13(9):e7159. doi: 10.1002/cam4.7159. Cancer Med. 2024. PMID: 38741546 Free PMC article. Review.
Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced/Metastatic NSCLC.
Burotto M, Zvirbule Z, Alvarez R, Chewaskulyong B, Herraez-Baranda LA, Shearer-Kang E, Liu X, Tosti N, Williams P, Castro Sanchez AY, Zanghi J, Felip E. Burotto M, et al. Among authors: felip e. J Thorac Oncol. 2024 May 8:S1556-0864(24)00210-7. doi: 10.1016/j.jtho.2024.05.005. Online ahead of print. J Thorac Oncol. 2024. PMID: 38729426 Free article.
Drug Cost Avoidance Resulting from Participation in Clinical Trials: A 10-Year Retrospective Analysis of Cancer Patients with Solid Tumors.
Carreras MJ, Renedo-Miró B, Valdivia C, Tomás-Guillén E, Farriols A, Mañós L, Vidal J, Alcalde M, De la Paz I, Jiménez-Lozano I, Palacio-Lacambra ME, Sabaté N, Felip E, Garralda E, Garau M, Gorgas MQ, Monterde J, Tabernero J. Carreras MJ, et al. Among authors: felip e. Cancers (Basel). 2024 Apr 17;16(8):1529. doi: 10.3390/cancers16081529. Cancers (Basel). 2024. PMID: 38672610 Free PMC article.
549 results